Publications & Presentations
Until a relevant regulatory agency has approved a Cara Therapeutics product for a specific disease or population, any scientific publication or presentation regarding such disease or population is not to be considered instructions on the use of the Cara Therapeutics product or clinical development candidate.
Until a relevant regulatory agency has approved a Cara Therapeutics product for a specific disease or population, any scientific publication or presentation regarding such disease or population is not to be considered instructions on the use of the Cara Therapeutics product or clinical development candidate.
Pruritus in Dialysis Dependent Chronic Kidney Disease
- A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
Fishbane S, et al. New England Journal of Medicine. 2020;382: 222-232
- Efficacy and Safety of Difelikefalin for Moderate-to-Severe Chronic Kidney Disease-Associated Pruritus: a Global Phase 3 Study in Hemodialysis Patients (KALM-2)
Woolridge T, et al. Presented at the American Society of Nephrology Kidney Week, 2020
- Reduction of Pruritus by Difelikefalin Correlates with Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis
Shirazian S, et al. Presented at the National Kidney Foundation Spring Clinical Meetings, 2022
- Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
Fishbane S, et al. Kidney International Reports. 2020;5: 600-610
- An Open-label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous Difelikefalin in Patients with Moderate-to-Severe Pruritus Undergoing Hemodialysis
Weiner D, et al. Presented at the European Renal Association – European Dialysis and Transplant Association Congress, 2021.
Pruritus in Non-Dialysis Dependent Chronic Kidney Disease
- Efficacy and Safety of Oral Difelikefalin in Chronic Kidney Disease With Moderate-to-Severe Pruritus: A Randomised, Placebo-Controllled, Phase 2 Trial
Yosipovitch G, et al. Presented at the American Academy of Dermatology Annual Meeting, 2020
Pruritus in Atopic Dermatitis
- Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis
Kim B, et al. Presented at the European Academy of Dermatology and Venereology Congress, 2021
- Oral Difelikefalin Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Subject With Moderate-to-Severe Pruritus
Guttman-Yassky E, et al. Presented at the American Academy of Dermatology Annual Meeting, 2022
Supportive Manuscripts on Difelikefalin
- Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agaonist, in recreational polydrug users
Shram M, et al. Clinical and Translational Science. 2022;15: 535-547
- Effect of difelikefalin, a selective kappa-opioid receptor agaonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial
Viscusi E, et al. Clinical and Translational Science. 2021;14: 1886-1893
Validation of Patient-Reported Outcomes
- Pyschometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Vernon M, et al. Journal of Patient-Reported Outcomes. 2021;5: 1-12
- Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus
Vernon M, et al. Journal of the American Academy of Dermatology. 2021;84: 1132-1134